obesity therapy development

Advertisement

cGxPJobs Banner

Samsung Bioepis Signs Deal to Develop Long-Acting Semaglutide

INCHEON, South Korea, March 16, 2026 Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd. have announced a strategic...

By cGxPwire Editor
March 16, 2026

Read More

Advertisement

cGxPJobs

Directory